<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03529539</url>
  </required_header>
  <id_info>
    <org_study_id>PSV</org_study_id>
    <nct_id>NCT03529539</nct_id>
  </id_info>
  <brief_title>Expanded Access for PSV Personalized Oncolytic Viruses</brief_title>
  <acronym>PSV</acronym>
  <official_title>Expanded Access for PSV Personalized Oncolytic Viruses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EpicentRx, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EpicentRx, Inc.</source>
  <brief_summary>
    <textblock>
      A compassionate use, expanded access protocol for patients who have exhausted all standard
      therapy having progressed on chemotherapy and immunotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will receive intratumoral or subcutaneous injection of an oncolytic virus called PSV
      (short for Personalized Virus) every other week until the occurrence of immune related RECIST
      progression, intolerable toxicity, change to another anti-cancer treatment due to lack of
      apparent benefit, or personal choice.
    </textblock>
  </detailed_description>
  <overall_status>No longer available</overall_status>
  <study_type>Expanded Access</study_type>
  <expanded_access_info>
    <expanded_access_type_individual>Yes</expanded_access_type_individual>
  </expanded_access_info>
  <condition>Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PSV</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to understand and sign a written informed consent form.

          -  Measurable or evaluable disease with least one (1) tumor that is accessible to
             intratumoral injection.

          -  Eastern Cooperative Group (ECOG) performance status is 0-3 at Screening.

          -  Acceptable liver function at Screening, as evidenced by:

               -  Bilirubin ≤ 3.0 X upper limit of normal (ULN) since this patient has

               -  been diagnosed with Gilbert's Disease

          -  AST (SGOT) and ALT (SGPT) ≤ 5 X ULN.

          -  Serum creatinine &lt; 3 x institution upper limit of normal.

          -  Patient has acceptable hematologic status at Screening, as evidenced by:

               -  Absolute neutrophil count ≥ 1,500 cells/mm3; and

               -  Platelet count ≥ 70,000/mm3; and

               -  Hemoglobin (HGB) ≥ 8.5 g/dL.

          -  Medically acceptable contraception.

          -  Willingness to comply with all protocol procedures, evaluations and rescue measures.

        Exclusion Criteria:

          -  Presence of a serious co-morbid medical condition, or a clinically significant
             laboratory finding(s) that, in the opinion of the Investigator, suggests the presence
             of an infectious, endocrine, and/or other inadequately treated systemic disorder.

          -  An active bacterial, fungal, or viral infection.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>John Morris, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cincinnati</affiliation>
  </overall_official>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>May 7, 2018</study_first_submitted>
  <study_first_submitted_qc>May 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2018</study_first_posted>
  <last_update_submitted>March 4, 2019</last_update_submitted>
  <last_update_submitted_qc>March 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

